{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:15:12Z","timestamp":1790234112111,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007582","name":"Alberta Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jcyt.2019.11.002","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:42:11Z","timestamp":1577407331000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era"],"prefix":"10.1016","volume":"22","author":[{"given":"Christopher","family":"Evernden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Dowhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosy","family":"Dabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Dharmani-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gregson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-7312","authenticated-orcid":false,"given":"Jennifer","family":"Jupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Jamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0001","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/bmt.2015.316","article-title":"The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis","volume":"51","author":"Williams","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2019.11.002_bib0002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1399-3062.1999.10105.x","article-title":"Preventing opportunistic infections in bone marrow transplant recipients","volume":"1","author":"Dykewicz","year":"1999","journal-title":"Transpl Infect Dis."},{"key":"10.1016\/j.jcyt.2019.11.002_bib0003","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","article-title":"Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study","volume":"36","author":"De Castro","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2019.11.002_bib0004","first-page":"1057","article-title":"Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation","volume":"17","author":"Lyytik\u00e4inen","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2019.11.002_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199001183220304","article-title":"The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group","volume":"322","author":"Phair","year":"1990","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jcyt.2019.11.002_bib0006","first-page":"1","volume":"58","author":"Masur","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jcyt.2019.11.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/2325958218759199","article-title":"The Impact of Absolute CD4 Count and Percentage Discordance on Pneumocystis Jirovecii Pneumonia Prophylaxis in HIV-Infected Patients","volume":"17","author":"Anyimadu","year":"2018","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0008","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1086\/515658","article-title":"Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis","volume":"178","author":"Kaplan","year":"1998","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jcyt.2019.11.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12651","article-title":"The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review","volume":"19","author":"Messiaen","year":"2017","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"10.1016\/j.jcyt.2019.11.002_bib0010","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12b","key":"10.1016\/j.jcyt.2019.11.002_bib0011","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern Med J"},{"issue":"9","key":"10.1016\/j.jcyt.2019.11.002_bib0012","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0013","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","article-title":"Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients","volume":"17","author":"Rodriguez","year":"2004","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"10.1016\/j.jcyt.2019.11.002_bib0014","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archinte.1995.00430110015002","article-title":"Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk","volume":"155","author":"Sepkowitz","year":"1995","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.jcyt.2019.11.002_bib0015","first-page":"1283","article-title":"The value of Pneumocystis carinii antibody and antigen detection for diagnosis of Pneumocystis carinii pneumonia after marrow transplantation","volume":"120","author":"Meyers","year":"1979","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.jcyt.2019.11.002_bib0016","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/clinids\/4.6.1119","article-title":"Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience","volume":"4","author":"Meyers","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"3","key":"10.1016\/j.jcyt.2019.11.002_bib0017","first-page":"267","article-title":"Pneumocystis carinii pneumonitis following bone marrow transplantation","volume":"10","author":"Tuan","year":"1992","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2019.11.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx050","article-title":"Infections in hematopoietic cell transplant recipients: Results from the organ transplant infection project, a multicenter, prospective, cohort study","volume":"4","author":"Schuster","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.jcyt.2019.11.002_bib0019","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bmt.1704162","article-title":"Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation","volume":"32","author":"Chen","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2019.11.002_bib0020","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jcyt.2019.11.002_bib0021","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2019.11.002_bib0022","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jcyt.2019.11.002_bib0023","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3109\/14653249.2012.715243","article-title":"et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation","volume":"14","author":"Bosch","year":"2012","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.jcyt.2019.11.002_bib0024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/152581603321628377","article-title":"Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation","volume":"12","author":"Fehse","year":"2003","journal-title":"J Hematother Stem Cell Res"},{"issue":"1","key":"10.1016\/j.jcyt.2019.11.002_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3324\/haematol.2012.067611","article-title":"Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients","volume":"98","author":"Na","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jcyt.2019.11.002_bib0026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2011.07.015","article-title":"Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing","volume":"18","author":"Kangarloo","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2019.11.002_bib0027","first-page":"83","article-title":"Influence of busulfan exposure on allogeneic transplant outcome using a fludarabine\/busulfan\/thymoglobulin\/total body irradiation preparative regimen for adult acute myelogenous leukemia","volume":"45","author":"Lewis","year":"2010","journal-title":"Bone Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0028","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbmt.2009.11.017","article-title":"The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia","volume":"16","author":"Russell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2019.11.002_bib0029","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2019.11.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2019.11.002_bib0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1155\/2015\/138787","article-title":"Development and validation of a Pneumocystis jirovecii real-time polymerase chain reaction assay for diagnosis of Pneumocystis pneumonia","volume":"26","author":"Church","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"3","key":"10.1016\/j.jcyt.2019.11.002_bib0032","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.diagmicrobio.2017.08.001","article-title":"Evaluation of quantitative FTD-Pneumocystis jirovecii kit for Pneumocystis infection diagnosis","volume":"89","author":"Hoarau","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.jcyt.2019.11.002_bib0033","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2217\/fmb.09.116","article-title":"Current understanding of Pneumocystis immunology","volume":"5","author":"Kelly","year":"2010","journal-title":"Future Microbiol"},{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00277-013-1698-0","volume":"92","author":"Neumann","year":"2013","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.jcyt.2019.11.002_bib0035","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3109\/10428194.2010.506569","article-title":"Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy","volume":"51","author":"Hashimoto","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jcyt.2019.11.002_bib0036","first-page":"478","article-title":"Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection","volume":"41","author":"Su","year":"2008","journal-title":"J Microbiol Immunol Infect"},{"issue":"26","key":"10.1016\/j.jcyt.2019.11.002_bib0037","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","article-title":"A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group","volume":"327","author":"Schneider","year":"1992","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jcyt.2019.11.002_bib0038","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-122-10-199505150-00004","article-title":"Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV","volume":"122","author":"Podzamczer","year":"1995","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jcyt.2019.11.002_bib0039","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199503163321101","article-title":"A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"Bozzette","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0040","first-page":"341","article-title":"Comparative trial of dapsone versus trimethoprim\/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia","volume":"5","author":"Blum","year":"1992","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0041","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1086\/520433","article-title":"A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)","volume":"29","author":"El-Sadr","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jcyt.2019.11.002_bib0042","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/archinte.1992.00400150053009","article-title":"A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients","volume":"152","author":"Martin","year":"1992","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.jcyt.2019.11.002_bib0043","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1128\/AAC.35.9.1705","article-title":"Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients","volume":"35","author":"Stein","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jcyt.2019.11.002_bib0044","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2133.1979.tb01644.x","article-title":"Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage","volume":"100","author":"Manfredi","year":"1979","journal-title":"Br J Dermatol"},{"issue":"15","key":"10.1016\/j.jcyt.2019.11.002_bib0045","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/cncr.25904","article-title":"Dapsone-induced methemoglobinemia: a dose-related occurrence?","volume":"117","author":"Esbenshade","year":"2011","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.jcyt.2019.11.002_bib0046","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJM199104183241602","article-title":"A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia","volume":"324","author":"Hirschel","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcyt.2019.11.002_bib0047","first-page":"490","article-title":"Breakthrough Pneumocystis jiroveci pneumonia under pentamidine prophylaxis: imaging findings revisited","volume":"15","author":"Pua","year":"2009","journal-title":"Hong Kong Med J"},{"issue":"5","key":"10.1016\/j.jcyt.2019.11.002_bib0048","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1183\/09031936.96.09051006","article-title":"Effect of long-term primary aerosolized pentamidine prophylaxis on breakthrough Pneumocystis carinii pneumonia","volume":"9","author":"Ewig","year":"1996","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcyt.2019.11.002_bib0049","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1399-3062.2002.t01-1-00008.x","article-title":"Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation","volume":"4","author":"Marras","year":"2002","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2019.11.002_bib0050","unstructured":"Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Unpublished raw data."},{"issue":"5","key":"10.1016\/j.jcyt.2019.11.002_bib0051","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9163","key":"10.1016\/j.jcyt.2019.11.002_bib0052","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(98)07399-1","article-title":"Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, C\u00f4te d'Ivoire: a randomised trial. Cotrimo-CI Study Group","volume":"353","author":"Anglaret","year":"1999","journal-title":"Lancet"},{"issue":"9448","key":"10.1016\/j.jcyt.2019.11.002_bib0053","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0140-6736(04)17442-4","article-title":"Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial","volume":"364","author":"Chintu","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcyt.2019.11.002_bib0054","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00126334-200102010-00004","article-title":"Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal","volume":"26","author":"Maynart","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.jcyt.2019.11.002_bib0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/thx.41.5.345","article-title":"Value of bronchoalveolar lavage in the diagnosis of pulmonary infection in acquired immune deficiency syndrome","volume":"41","author":"Orenstein","year":"1986","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcyt.2019.11.002_bib0056","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1034\/j.1399-3062.2001.003001002.x","article-title":"Diagnostic yield of bronchoalveolar lavage following renal transplantation","volume":"3","author":"Reichenberger","year":"2001","journal-title":"Transpl Infect Dis"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919308928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919308928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:39:36Z","timestamp":1761442776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324919308928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1465324919308928"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.11.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019. Published by Elsevier Inc. on behalf of International Society for Cell and Gene Therapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}